Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 25, 2009

Daiichi Sankyo Obtains Rights to Gene Bridges’ Recombineering Technology

  • Daiichi Sankyo has inked a commercial license agreement for the use of the Red/ET recombination technology from Gene Bridges. The Red/ET recombination technology is a method for generating targeting vectors or modifying E. coli chromosomes.
     
    According to Gene Bridges, recombineering with Red/ET allows cloning, subcloning, and modification of DNA at any chosen position. It permits precise engineering of DNA molecules of any size, including large ones such as BACs or the E.coli chromosome.

     



Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »